Laurus Labs Ltd
LAURUSLABSBSE 540222PharmaceuticalsMkt cap ₹1,07,468 Cr
Whole group, including subsidiaries — the figures companies headline.
Revenue · Q1 FY27
₹2,026 Cr
YoY +29.1%QoQ +11.9%
Net profit · Q1 FY27
₹362 Cr
YoY +123.9%QoQ +28.4%
Net margin · Q1 FY27
17.9%
+7.6 pts vs Q1 FY26
Net profit · FY26
₹890 Cr
YoY +148.4%
Quarterly results
| ₹ Cr | Q1 FY27 Apr–Jun 2026 | Q4 FY26 Jan–Mar 2026 | Q3 FY26 Oct–Dec 2025 | Q2 FY26 Jul–Sep 2025 | Q1 FY26 Apr–Jun 2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | 2,026 | 1,812 | 1,778 | 1,653 | 1,570 | +29.1% |
| Other income | 9.18 | 11.80 | 5.76 | 26.96 | 10.43 | -12.0% |
| Total income | 2,035 | 1,823 | 1,784 | 1,680 | 1,580 | +28.8% |
| Profit before tax | 481 | 361 | 327 | 270 | 224 | +114.7% |
| Tax | 119 | 79.46 | 73.45 | 75.98 | 63.14 | +89.1% |
| Net profit | 362 | 282 | 252 | 194 | 162 | +123.9% |
| Net margin | 17.9% | 15.6% | 14.2% | 11.8% | 10.3% |
Annual results
| ₹ Cr | FY26 Apr 2025–Mar 2026 | FY25 Apr 2024–Mar 2025 | FY24 Apr 2023–Mar 2024 | FY23 Apr 2022–Mar 2023 | FY22 Apr 2021–Mar 2022 | YoY |
|---|---|---|---|---|---|---|
| Revenue | 6,813 | 5,554 | 5,041 | 6,041 | 4,936 | +22.7% |
| Other income | 54.95 | 75.10 | 26.34 | 6.00 | 15.30 | -26.8% |
| Total income | 6,868 | 5,629 | 5,067 | 6,047 | 4,951 | +22.0% |
| Profit before tax | 1,182 | 484 | 236 | 1,109 | 1,084 | +144.0% |
| Tax | 292 | 130 | 68.15 | 312 | 251 | +124.8% |
| Net profit | 890 | 358 | 162 | 793 | 832 | +148.4% |
| Net margin | 13.1% | 6.5% | 3.2% | 13.1% | 16.9% |
BIC's take
We haven't covered Laurus Labs Ltd yet. Browse our sector reports →
Source: BSE filings · Data as of 2 Oct 2026, 5:35 pm IST· ₹ crore unless stated. Covers BSE 500 companies only. Consolidated figures include subsidiaries; standalone is the parent company alone. Growth is shown only against a positive base. Not investment advice — check the company's full filing before acting.